86 selected records with a cited source date in 2014. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT01128192 at 2026-11-15T22:05:38.400Z. Its registry update date was 2014-12-25, and PeptideScanner's reviewed identity mapping was pasireotide.
The official Drugs@FDA dataset lists original submission 1 for NDA 206321 with status AP dated 2014-12-23, and names liraglutide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01382719 at 2026-07-30T21:54:46.551Z. Its registry update date was 2014-12-18, and PeptideScanner's reviewed identity mapping was bremelanotide.
The Federal Register published notice 2014-28702, attributed to FDA and its parent HHS department, on 2014-12-09. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01507389 at 2026-07-30T21:54:46.547Z. Its registry update date was 2014-12-09, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01435083 at 2026-11-16T01:33:21.554Z. Its registry update date was 2014-12-05, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00317395 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-12-03, and PeptideScanner's reviewed identity mapping was eptifibatide.
PeptideScanner retained ClinicalTrials.gov record NCT02305069 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-12-02, and PeptideScanner's reviewed identity mapping was octreotide.
PeptideScanner retained ClinicalTrials.gov record NCT00412061 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-11-21, and PeptideScanner's reviewed identity mapping was octreotide.
PubMed lists PMID 6412255 in Die Pharmazie as English Abstract, Journal Article, with publication-date metadata of 1983-06 (month precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 17418383 in The Journal of allergy and clinical immunology as Clinical Trial, Phase I, Journal Article, with publication-date metadata of 2007-04-05 (day precision). PeptideScanner associated the retained record with the identity slug icatibant. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 20533892 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2010-07 (month precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 21496210 in Basic & clinical pharmacology & toxicology as Journal Article, with publication-date metadata of 2011-05-23 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 22674191 in The Prostate as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-06-05 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23669783 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2013-05-13 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23680921 in Cancer chemotherapy and pharmacology as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 14963471 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2004-02-14. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 15134289 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2004-05-12. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 17151329 at 2026-07-30T21:55:37.962Z. PubMed recorded a metadata revision date of 2014-11-20 and an Entrez history date of 2006-12-08. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT00379522 at 2026-11-15T22:08:31.832Z. Its registry update date was 2014-11-05, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01645241 at 2026-11-15T22:03:26.540Z. Its registry update date was 2014-10-27, and PeptideScanner's reviewed identity mapping was ganirelix.
DailyMed lists Structured Product Labeling version 5 for the reviewed Dulaglutide label family with a published date of 2014-10-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01524770 at 2026-07-30T21:54:46.539Z. Its registry update date was 2014-10-22, and PeptideScanner's reviewed identity mapping was dulaglutide.
The Federal Register published notice 2014-23961, attributed to FDA and its parent HHS department, on 2014-10-08. Its official title is “Determination That LUPRON DEPOT (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01432938 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01436201 at 2026-07-30T21:54:46.550Z. Its registry update date was 2014-10-07, and PeptideScanner's reviewed identity mapping was dulaglutide.
DailyMed lists Structured Product Labeling version 4 for the reviewed Dulaglutide label family with a published date of 2014-10-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01166958 at 2026-07-30T21:54:46.558Z. Its registry update date was 2014-09-22, and PeptideScanner's reviewed identity mapping was teriparatide.
PubMed lists PMID 25003365 in Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2014-07-08 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for BLA 125469 with status AP dated 2014-09-18, and names dulaglutide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 202857 with status AP dated 2014-09-12, and names daptomycin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01270789 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01237197 at 2026-07-30T21:54:46.554Z. Its registry update date was 2014-09-12, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00573144 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-09-09, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00801242 at 2026-11-15T21:52:09.579Z. Its registry update date was 2014-09-03, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT01132846 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-08-21, and PeptideScanner's reviewed identity mapping was nesiritide.
The Federal Register published notice 2014-19713, attributed to FDA and its parent HHS department, on 2014-08-20. Its official title is “Determination That LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 3.75 Milligrams/Vial and 7.5 Milligrams/Vial; and LUPRON DEPOT-PED (Leuprolide Acetate for Depot Suspension), Injectable 7.5 Milligrams/Vial and 7.5 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide.
PeptideScanner retained PubMed bibliographic metadata for PMID 15003204 at 2026-07-30T21:55:37.950Z. PubMed recorded a metadata revision date of 2014-08-18 and an Entrez history date of 2004-03-09. PeptideScanner associated this retained record with the identity slug lanreotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT01534182 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-08-08, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
The Federal Register published notice 2014-18304, attributed to FDA and its parent HHS department, on 2014-08-04. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01549613 at 2026-11-15T22:01:45.056Z. Its registry update date was 2014-08-01, and PeptideScanner's reviewed identity mapping was daptomycin.
PubMed lists PMID 19538002 in Expert opinion on drug metabolism & toxicology as Journal Article, Review, with publication-date metadata of 2009-07 (month precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The Federal Register published notice 2014-17293, attributed to FDA and its parent HHS department, on 2014-07-23. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Lanreotide.
DailyMed lists Structured Product Labeling version 7 for the reviewed Linaclotide label family with a published date of 2014-07-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01109654 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-07-16, and PeptideScanner's reviewed identity mapping was cetrorelix.
DailyMed lists Structured Product Labeling version 6 for the reviewed Linaclotide label family with a published date of 2014-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT01354405 at 2026-07-30T21:54:46.540Z. Its registry update date was 2014-07-09, and PeptideScanner's reviewed identity mapping was lanreotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 200653 with status AP dated 2014-06-27, and names desmopressin acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01440881 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-06-06, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01669291 at 2026-07-30T21:54:46.557Z. Its registry update date was 2014-06-04, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00521300 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-06-02, and PeptideScanner's reviewed identity mapping was octreotide.
PubMed lists PMID 24768406 in International journal of pharmaceutics as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2014-04-23 (day precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.
The Federal Register published notice 2014-11926, attributed to FDA and its parent HHS department, on 2014-05-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; LINZESS,” and PeptideScanner's exact reviewed identity mapping connects the document to Linaclotide.
The Federal Register published notice 2014-11523, attributed to FDA and its parent HHS department, on 2014-05-20. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OMONTYS,” and PeptideScanner's exact reviewed identity mapping connects the document to Peginesatide.
The Federal Register published notice 2014-11175, attributed to FDA and its parent HHS department, on 2014-05-15. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; KYPROLIS,” and PeptideScanner's exact reviewed identity mapping connects the document to Carfilzomib.
PeptideScanner retained ClinicalTrials.gov record NCT01088529 at 2026-07-30T21:54:46.544Z. Its registry update date was 2014-05-15, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01160328 at 2026-07-30T21:54:46.559Z. Its registry update date was 2014-05-14, and PeptideScanner's reviewed identity mapping was leuprolide.
FDA's dated enforcement report D-1287-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
FDA's dated enforcement report D-1288-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
FDA's dated enforcement report D-1289-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020263 through exact openFDA application-number annotations.
FDA's dated enforcement report D-1290-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020708 through exact openFDA application-number annotations.
FDA's dated enforcement report D-1291-2014 lists Class II and source status Terminated for AbbVie Inc. PeptideScanner connects the report to reviewed application NDA020517 through exact openFDA application-number annotations.
PeptideScanner retained ClinicalTrials.gov record NCT00624195 at 2026-11-16T01:41:15.051Z. Its registry update date was 2014-04-23, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00894803 at 2026-11-15T21:59:29.646Z. Its registry update date was 2014-04-17, and PeptideScanner's reviewed identity mapping was eptifibatide.
The official Drugs@FDA dataset lists original submission 1 for NDA 204485 with status AP dated 2014-04-17, and names vasopressin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for BLA 125431 with status AP dated 2014-04-15, and names albiglutide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01465503 at 2026-11-15T21:58:19.888Z. Its registry update date was 2014-04-08, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00211887 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-04-03, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
The Federal Register published notice 2014-07331, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; FIRAZYR,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.
The Federal Register published notice 2014-07330, attributed to FDA and its parent HHS department, on 2014-04-02. Its official title is “Draft and Revised Draft Guidances for Industry Describing Product-Specific Bioequivalence Recommendations; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.
The Federal Register published rule 2014-06131, attributed to FDA and its parent HHS department, on 2014-03-25. Its official title is “Implantation or Injectable Dosage Form New Animal Drugs; Change of Sponsor,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
PeptideScanner retained ClinicalTrials.gov record NCT00405639 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-03-17, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01225835 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-03-14, and PeptideScanner's reviewed identity mapping was cetrorelix.
PeptideScanner retained ClinicalTrials.gov record NCT01611571 at 2026-07-30T21:54:46.552Z. Its registry update date was 2014-03-04, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00813202 at 2026-11-16T01:39:41.882Z. Its registry update date was 2014-02-28, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01550653 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-27, and PeptideScanner's reviewed identity mapping was liraglutide.
The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01185704 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-02-13, and PeptideScanner's reviewed identity mapping was cetrorelix.
The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT01216072 at 2026-11-16T17:42:50.457Z. Its registry update date was 2014-02-10, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT01093729 at 2026-11-16T17:34:46.889Z. Its registry update date was 2014-02-07, and PeptideScanner's reviewed identity mapping was efpeglenatide.
PeptideScanner retained ClinicalTrials.gov record NCT01916265 at 2026-07-30T21:54:46.545Z. Its registry update date was 2014-02-05, and PeptideScanner's reviewed identity mapping was glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01250717 at 2026-11-15T21:50:32.222Z. Its registry update date was 2014-02-04, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin.
PeptideScanner retained ClinicalTrials.gov record NCT00003124 at 2026-07-30T21:54:46.538Z. Its registry update date was 2014-01-06, and PeptideScanner's reviewed identity mapping was leuprolide.